Navigation Links
Alzheimer's progression tracked prior to dementia
Date:9/23/2013

e path to Alzheimer's dementia will help us improve the design and assessment of clinical trials," said senior author Anne Fagan, PhD, research professor of neurology. "There are many steps left before we can apply this system in the clinic, including standardizing how we gather and assess data in individuals, and determining which of our indicators of preclinical disease are the most accurate. But the research data are compelling and very encouraging."

The classification system divides preclinical Alzheimer's into three stages:

Stage 1: Levels of amyloid beta, a protein fragment produced by the brain, begin to fall in the spinal fluid. This indicates that the substance is beginning to form plaques in the brain.

Stage 2: Levels of tau protein start to rise in the spinal fluid, indicating that brain cells are beginning to die. Amyloid beta levels are still abnormal and may continue to fall.

Stage 3: In the presence of abnormal amyloid and tau biomarker levels, subtle cognitive changes can be detected by neuropsychological testing. By themselves, these changes cannot establish a clinical diagnosis of dementia.

The researchers applied these criteria to research participants studied from 1998 through 2011 at the Knight Alzheimer Disease Research Center. The center annually collects extensive cognitive, biomarker and other health data on normal and cognitively impaired volunteers for use in Alzheimer's studies.

The scientists analyzed information on 311 individuals age 65 or older who were cognitively normal when first evaluated. Each participant was evaluated annually at the center at least twice; the participant in this study with the most data had been followed for 15 years.

At the initial testing, 41 percent of the participants had no indicators of Alzheimer's disease (stage 0); 15 percent were in stage 1 of preclinical disease; 12 percent were in stage 2; and 4 percent were in stage 3. The remaining part
'/>"/>

Contact: Michael C. Purdy
purdym@wustl.edu
314-286-0122
Washington University School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Immunoglobulins Market to 2019 - Demand in Primary Immunodeficiency And CIDP Potentially Supplemented by Approval for Alzheimers Disease Available at ResearchMoz.us
2. Early Use of MS Drug May Cut Likelihood of Progression
3. RANK protein promotes the initiation, progression and metastasis of human breast cancer
4. Biosynthetic grape-derived compound prevents progression of Alzheimers disease in mice
5. Drug Widely Used to Treat MS May Not Slow Progression
6. Infection With 2 HIV Strains Slows Disease Progression
7. Tumor cells inner workings predict cancer progression
8. Wayne State research team finds possible clue to progression of MS
9. Alzheimers Progression Slower After 80: Study
10. New gene variants raise risk of neuroblastoma, influence tumor progression
11. Moffitt cancer center researchers find novel predictor for MDS progression risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 04, 2015 The print component of ... San Francisco Chronicle with a circulation of approximately 173,000 ... digital component is distributed nationally through a vast social ... sites and partner outlets. To explore the digital version ... Milorganite is composed of heat-dried microbes that have digested ...
(Date:3/4/2015)... Houston, Texas (PRWEB) March 04, 2015 ... blog , Endometriosis can be a painful ... endometrium) starts spreading outside of the uterus leading to ... and their families. Endometriosis can have a terrible effect ... symptoms. It is also the most common cause of ...
(Date:3/4/2015)... March 04, 2015 The popular all-natural ... their new L-Style Revolution™ Program. The customized program provides ... women of all health and fitness levels to follow ... faster than traditional methods. , “We’re really proud to ... plans based on award winning techniques to help people ...
(Date:3/4/2015)... California (PRWEB) March 04, 2015 RapidScale, ... 2015, in Las Vegas, Nevada, on March 16th-18th. They ... RapidScale will have some of its top engineering executives ... advances in the RapidScale solution set. Attendees include William ... Senior Cloud Engineer; and Ryan Turpin, Cloud Support Manager. ...
(Date:3/4/2015)... 2015 SIGVARIS proved innovative ... their first compression therapy collection designed exclusively for men. ... SIGVARIS USA is proud to announce the launch of ... , Constructed from a unique, extremely fine synthetic fiber, ... These socks and thigh-highs offer a tailored look that ...
Breaking Medicine News(10 mins):Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 2Health News:Advanced Fertility Center of Texas Brings Awareness to the Month of March-Endometriosis Awareness Month 3Health News:The Makers of Liporidex, The Popular Sports Nutrition Supplement Brand, Launches Its New L-Style Revolution™ Diet & Exercise Program That Promises Turbo Charged Results 2Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 2Health News:Rapidscale to Host First Cloudtalk Events at Channel Partners in Las Vegas 3Health News:Building on the Success of MIDTOWN MICROFIBER, SIGVARIS Expands Popular Compression Collection with Longer Foot Length Offerings 2
... 90-Day Supply of More Than 400,Generic Drugs for ... WOONSOCKET, R.I., Oct. 30 Today,CVS/pharmacy, the ... care savings program aimed at helping the uninsured ... obtain a,CVS/pharmacy Health Savings Pass for a $10 ...
... clocks to summer time on the last Sunday in March ... In return, putting the clocks back in the autumn reduces ... a new Swedish study published in the prestigious New ... have examined how the incidence of myocardial infarction in Sweden ...
... and ... Milk Their Diets, HOUSTON, Oct. 30 The last decade ... seem to go in and out of,fashion like shoulder pads and hemlines. Yet, ... Texas residents --,remain overweight or obese., A new campaign crossing the country, ...
... TeleHealth Services, Inc., a,leading provider of integrated communication ... Barker to the new position of Director of,Marketing. ... research and analysis., After a comprehensive search, ... efforts for its comprehensive line of integrated,hospital television ...
... Arno Therapeutics,Inc. (OTC Bulletin Board: ARNI.OB), a ... the appointment,of William F. Hamilton, Ph.D. to its ... committee. Dr. Hamilton has over 40 years experience ... expertise in the areas of,technology strategy and planning, ...
... by Dr. David Katz, Director of Yale University,s,Prevention Research Center ... in Blood Pressure -, DERBY, Conn., Oct.30 Snacking ... help with weight control, according to a recently,completed pilot study ... overweight adults consumed two KIND Fruit & Nut Delight,Bars per ...
Cached Medicine News:Health News:CVS/pharmacy Announces Pharmacy Health Care Savings Program Targeted at the Uninsured 2Health News:CVS/pharmacy Announces Pharmacy Health Care Savings Program Targeted at the Uninsured 3Health News:Clock-shifts affect risk of heart attack 2Health News:Message to Houston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 2Health News:Message to Houston Residents: Forgo Fad Dieting and Join the Campaign for Healthy Weight 3Health News:TeleHealth Names Matthew K. Barker to New Director of Marketing Position 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 3Health News:Daily Snack Bars May Facilitate Weight Loss 2Health News:Daily Snack Bars May Facilitate Weight Loss 3Health News:Daily Snack Bars May Facilitate Weight Loss 4
(Date:3/4/2015)... N.Y. , March 4, 2015  Kannalife Sciences, ... MD has joined its Scientific Advisory Board to assist ... development efforts towards the use of cannabinoid therapeutics for ... is the forensic pathologist responsible for conducting the full ... Hall of Fame center for the Pittsburgh Steelers. It ...
(Date:3/4/2015)... Mar. 04, 2015 Research and Markets ... of the "Negative Pressure Wound Therapy Market ... Industry Analysis, Size, Share, Growth, Trends and Forecast ... , The global negative pressure ... and by geography. By product types the NPWT ...
(Date:3/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... company focused on the development of oral drug delivery ... the upcoming 27 th Annual ROTH Conference, taking ... CA.  Dr. Michael Berelowitz , Chairman ... a corporate overview on March 10, 2015. ...
Breaking Medicine Technology:Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 2Kannalife Sciences, Inc. Announces the Addition of Dr. Bennet Omalu, Renowned Pathologist and Founder of Chronic Traumatic Encephalopathy, to its Scientific Advisory Board 3Global Negative Pressure Wound Therapy (Conventional and Single Use NPWT Systems) Market Report 2014-2020 2Oramed to Present at the ROTH Conference 2Oramed to Present at the ROTH Conference 3
... HIGHLIGHTS:2011 Results (all percentages are to ... reported sales increased 11% to $626 million. Q3 sales grew ... sales growing organically by 4% and 2%, respectively.  Recently completed ... exchange rates contributed an additional 5% to reported sales growth ...
... Merz Pharmaceuticals, LLC, today announced that data from ... Xeomin® (incobotulinumtoxinA), a botulinum toxin type A free from ... will be presented at the 115th Annual Meeting of ... These data include an extension of the ...
Cached Medicine Technology:Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 2Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 3Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 4Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 5Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 6Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 7Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 8Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 9Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 10Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 11Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 12Sigma-Aldrich (NASDAQ:SIAL) Reports 25% Increase in Q3 Diluted EPS. Q3 Sales Increase 11%. Full Year 2011 Diluted EPS Raised to $3.73 to $3.81. 13Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 2Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 3Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 4Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 5Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 6Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 7Data on Xeomin® (incobotulinumtoxinA) in the Treatment of Blepharospasm to be Presented at the 115th Annual Meeting of the American Academy of Ophthalmology 8
... Implants - Anatomically designed to enhance the chin ... the mandible with a high-profile central chin projection. ... the entire mandible, this implant provides a high ... extended arms. Cleft Chin Implants - Designed ...
... FL40 Centrifuge Series from Thermo Electron ... increase your productivity in the lab. ... rotors and accessories for high-volume blood ... IEC CL40 and FL40 Centrifuge Series ...
... Multispeed Series offers unsurpassed versatility and ... 1.2 liter benchtop centrifuge. With its ... and high-speed centrifugation capabilities, the IEC ... need to meet a variety of ...
... CL30 Series from Thermo delivers ... for your low-speed clinical applications. ... exchange system, user-friendly controls, and ... CL30 Series delivers solid performance ...
Medicine Products: